ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg may be appropriate for any patient with persistent diabetic macular edema (DME)

Consider ILUVIEN for the following patients with DME:

Consider ILUVIEN for vitrectomized patients. A small, retrospective European study describing treatment of vitrectomized eyes with ILUVIEN

Vitrectomized eyes were excluded from the FAME studies.

This recent European study reports retrospective data providing valuable clinical insights on the safety and efficacy of ILUVIEN in eyes with prior vitrectomy, since ILUVIEN is commonly used in vitrectomized eyes.1

LIMITATIONS OF STUDY

  • This is a small, retrospective study
  • Data were based on clinical practice, where there is reporting of non-standardized data, and the data may not be as rigorous as in a clinical trial where the data collection is monitored
  • The effect of the vitrectomy procedure on the duration of the intravitreal therapy is not fully understood
  • Further studies are required to confirm the current findings and assess the effect of ILUVIEN over a longer period of follow-up
  • The collection and reporting of this retrospective data with a relatively small number of patients and short period of follow-up post-therapy with ILUVIEN (mean = 8.5 months) should not be compared with the FAME pivotal studies, which provided 36 months of follow-up data
  • Study was performed in Europe, where clinical practice may be different. In Europe, ILUVIEN is approved for the treatment of visual impairment due to chronic DME considered insufficiently responsive to available therapies

Conflicts of Interest

Authors of this study received compensation from Alimera. Two authors received speaker honoraria from Alimera, and two authors were consultants. One author received reimbursement of travel expenses and study support from Alimera.

Observations from a small, real-world cohort of vitrectomized patients with DME treated with ILUVIEN

  • In this retrospective study of 26 vitrectomized eyes treated with ILUVIEN, visual acuity and retinal thickness improved (mean follow-up 8.5 months)1
  • 31% of patients had increases in intraocular pressure (IOP) that were managed with drops; none required surgery at the time of study publication
  • 2 patients in this study experienced migration of the ILUVIEN implant to the anterior chamber. In both cases, there was a history of capsular tear and ILUVIEN was surgically repositioned without further complication
  • Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber1

Change in visual acuity
from baseline (n=26)

Change in central retinal thickness
from baseline (n=26)

REAL-WORLD<br /><noscript><img src=
REAL-WORLD
DATA

Data from the USER Study confirm the efficacy of ILUVIEN
in a variety of patients with persistent DME.

PATIENT<br /><noscript><img src=
PATIENT
CASE STUDY

See why Dr. Haupert chose ILUVIEN for
a vitrectomized patient in his practice.